Next Article in Journal
Anti-Aggregative Effect of the Antioxidant DJ-1 on the TPPP/p25-Derived Pathological Associations of Alpha-Synuclein
Previous Article in Journal
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
Previous Article in Special Issue
Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer
 
 
Review

Novel Peptide Therapeutic Approaches for Cancer Treatment

1
Department of Molecular & Cellular Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
2
Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
3
Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Malathy Shekhar and Michael S. Simon
Cells 2021, 10(11), 2908; https://doi.org/10.3390/cells10112908
Received: 16 September 2021 / Revised: 12 October 2021 / Accepted: 21 October 2021 / Published: 27 October 2021
Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the peptide may be conjugated to a chemotherapy drug or radionuclide and used to target the agent to cancer cells. Peptides can be targeted to proteins on the cell surface, where the peptide–protein interaction can initiate internalization of the complex, or the peptide can be designed to directly cross the cell membrane. Peptides can induce cell death by numerous mechanisms including membrane disruption and subsequent necrosis, apoptosis, tumor angiogenesis inhibition, immune regulation, disruption of cell signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways. Although using peptides as therapeutics has many advantages, peptides have the disadvantage of being easily degraded by proteases once administered and, depending on the mode of administration, often have difficulty being adsorbed into the blood stream. In this review, we discuss strategies recently developed to overcome these obstacles of peptide delivery and bioavailability. In addition, we present many examples of peptides developed to fight cancer. View Full-Text
Keywords: drug delivery; peptide therapeutic; covalent-based peptide inhibitors; PCNA drug delivery; peptide therapeutic; covalent-based peptide inhibitors; PCNA
Show Figures

Graphical abstract

MDPI and ACS Style

Li, C.M.; Haratipour, P.; Lingeman, R.G.; Perry, J.J.P.; Gu, L.; Hickey, R.J.; Malkas, L.H. Novel Peptide Therapeutic Approaches for Cancer Treatment. Cells 2021, 10, 2908. https://doi.org/10.3390/cells10112908

AMA Style

Li CM, Haratipour P, Lingeman RG, Perry JJP, Gu L, Hickey RJ, Malkas LH. Novel Peptide Therapeutic Approaches for Cancer Treatment. Cells. 2021; 10(11):2908. https://doi.org/10.3390/cells10112908

Chicago/Turabian Style

Li, Caroline M., Pouya Haratipour, Robert G. Lingeman, J. Jefferson P. Perry, Long Gu, Robert J. Hickey, and Linda H. Malkas. 2021. "Novel Peptide Therapeutic Approaches for Cancer Treatment" Cells 10, no. 11: 2908. https://doi.org/10.3390/cells10112908

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop